Abstract
Objective: Osteoarthritis is a degenerative disease of the joints. Non-steroidal antiinflammatory drugs (NSAIDs) are being used for the treatment of osteoarthritis. However, their use is limited due to complications, such as gastrointestinal bleeding. Therefore, it is necessary to find alternative treatments for osteoarthritis. Recently, nanomicelle curcumin has been developed to increase the oral bioavailability of curcumin. The aim of this study was to evaluate the effect of nano curcumin on the alleviation of the symptoms of knee osteoarthritis patients.
Methods: In this randomized, double-blind controlled trial, the intervention group was administered 40 mg of nanocurcumin capsule every 12 hours over a period of six weeks, and the control group received the placebo (similar components of nanomicelle curcumin capsules yet without curcumin). In the final analysis, 36 patients in the nanocurcumin group and 35 patients in the placebo group were enrolled. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was filled for patients in their first visit and at the end of six weeks. Differences were statistically significant at P-value < 0.05.
Results: There were no significant differences between the two groups regarding gender, age, Kellgren score, and the duration of the disease before the intervention. A significant decrease was observed in the overall score, along with the scores of pain, stiffness and physical activity subscales of the WOMAC questionnaire in patients of the nano curcumin group compared with the placebo group.
Conclusion: Nanocurcumin significantly improves the symptoms of osteoarthritis patients.
Keywords: Nanomicelle curcumin, osteoarthritis, NSAIDs, WOMAC, age, kellgren score.
Graphical Abstract
[1]
Peddada KV, Peddada KV, Shukla SK, Mishra A, Verma V. Role of Curcumin in Common Musculoskeletal Disorders: a Review of Current Laboratory, Translational, and Clinical Data. Orthop Surg 2015; 7(3): 222-31.
[http://dx.doi.org/10.1111/os.12183] [PMID: 26311096]
[http://dx.doi.org/10.1111/os.12183] [PMID: 26311096]
[2]
Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58(1): 26-35.
[http://dx.doi.org/10.1002/art.23176] [PMID: 18163497]
[http://dx.doi.org/10.1002/art.23176] [PMID: 18163497]
[3]
Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994; 84(3): 351-8.
[http://dx.doi.org/10.2105/AJPH.84.3.351] [PMID: 8129049]
[http://dx.doi.org/10.2105/AJPH.84.3.351] [PMID: 8129049]
[4]
Aborehab NM, El Bishbishy MH, Refaiy A, Waly NE. A putative Chondroprotective role for IL-1β and MPO in herbal treatment of experimental osteoarthritis. BMC Complement Altern Med 2017; 17(1): 495.
[http://dx.doi.org/10.1186/s12906-017-2002-y] [PMID: 29166937]
[http://dx.doi.org/10.1186/s12906-017-2002-y] [PMID: 29166937]
[5]
Moshari S, Nejati V, Najafi G, Razi M. Insight into curcumin nanomicelle-induced derangements in male reproduction potential: An experimental study. Andrologia 2018; 50(2)
[http://dx.doi.org/10.1111/and.12842] [PMID: 29057491]
[http://dx.doi.org/10.1111/and.12842] [PMID: 29057491]
[6]
Moshari S, Nejati V, Najafi G, Razi M. Nanomicelle curcumin-induced DNA fragmentation in testicular tissue; Correlation between mitochondria dependent apoptosis and failed PCNA-related hemostasis. Acta Histochem 2017; 119(4): 372-81.
[http://dx.doi.org/10.1016/j.acthis.2017.03.007] [PMID: 28385400]
[http://dx.doi.org/10.1016/j.acthis.2017.03.007] [PMID: 28385400]
[7]
Yokoyama M. Polymeric micelles as drug carriers: their lights and shadows. J Drug Target 2014; 22(7): 576-83.
[http://dx.doi.org/10.3109/1061186X.2014.934688] [PMID: 25012065]
[http://dx.doi.org/10.3109/1061186X.2014.934688] [PMID: 25012065]
[8]
Ahmadi M, Agah E, Nafissi S, et al. Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. Neurotherapeutics 2018; 15(2): 430-8.
[http://dx.doi.org/10.1007/s13311-018-0606-7] [PMID: 29352425]
[http://dx.doi.org/10.1007/s13311-018-0606-7] [PMID: 29352425]
[9]
Rahimi HR, Mohammadpour AH, Dastani M, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed 2016; 6(5): 567-77.
[PMID: 27761427]
[PMID: 27761427]
[10]
Wu CW, Morrell MR, Heinze E, et al. Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. Semin Arthritis Rheum 2005; 35(3): 197-201.
[http://dx.doi.org/10.1016/j.semarthrit.2005.06.002] [PMID: 16325660]
[http://dx.doi.org/10.1016/j.semarthrit.2005.06.002] [PMID: 16325660]
[11]
Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16(4): 494-502.
[http://dx.doi.org/10.1136/ard.16.4.494] [PMID: 13498604]
[http://dx.doi.org/10.1136/ard.16.4.494] [PMID: 13498604]
[12]
Mahmoud Reza Jaafari, CURCUMIN NANOMICELLES FOR ORAL ADMINISTRATION, International application No PCT/IB2018/051370; International filing date: March 4, 2018; 2018
[13]
Konstantinidis GA, Aletras VH, Kanakari KA, Natsis K, Bellamy N, Niakas D. Comparative validation of the WOMAC osteoarthritis and Lequesne algofunctional indices in Greek patients with hip or knee osteoarthritis. Qual Life Res 2014; 23(2): 539-48.
[http://dx.doi.org/10.1007/s11136-013-0490-x] [PMID: 23918463]
[http://dx.doi.org/10.1007/s11136-013-0490-x] [PMID: 23918463]
[14]
Nadrian H, Moghimi N, Nadrian E, et al. Validity and reliability of the Persian versions of WOMAC Osteoarthritis Index and Lequesne Algofunctional Index. Clin Rheumatol 2012; 31(7): 1097-102.
[http://dx.doi.org/10.1007/s10067-012-1983-7] [PMID: 22526476]
[http://dx.doi.org/10.1007/s10067-012-1983-7] [PMID: 22526476]
[15]
Farid R, Mirfeizi Z, Mirheidari M, Rezaieyazdi Z, Mansouri H, Esmaelli H, et al. Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutr Res 2007; 27(11): 692-7.
[http://dx.doi.org/10.1016/j.nutres.2007.09.007]
[http://dx.doi.org/10.1016/j.nutres.2007.09.007]
[16]
Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A. Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-blind Placebo-controlled Trial. Drug Res (Stuttg) 2015; 65(11): 567-73.
[PMID: 25268878]
[PMID: 25268878]
[17]
Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012; 49(Pt 6): 580-8.
[http://dx.doi.org/10.1258/acb.2012.012040] [PMID: 23038702]
[http://dx.doi.org/10.1258/acb.2012.012040] [PMID: 23038702]
[18]
Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2014; 28(5): 633-42.
[http://dx.doi.org/10.1002/ptr.5045] [PMID: 23922235]
[http://dx.doi.org/10.1002/ptr.5045] [PMID: 23922235]
[19]
Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial. J Diet Suppl 2016; 13(2): 209-20.
[http://dx.doi.org/10.3109/19390211.2015.1008611] [PMID: 25688638]
[http://dx.doi.org/10.3109/19390211.2015.1008611] [PMID: 25688638]
[20]
Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutr 2015; 34(6): 1101-8.
[http://dx.doi.org/10.1016/j.clnu.2014.12.019] [PMID: 25618800]
[http://dx.doi.org/10.1016/j.clnu.2014.12.019] [PMID: 25618800]
[21]
Sahebkar A, Simental-Mendía LE, Giorgini P, Ferri C, Grassi D. Lipid profile changes after pomegranate consumption: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine 2016; 23(11): 1103-12.
[http://dx.doi.org/10.1016/j.phymed.2015.12.014] [PMID: 26857863]
[http://dx.doi.org/10.1016/j.phymed.2015.12.014] [PMID: 26857863]
[22]
Sahebkar A, Henrotin Y. Analgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Med 2016; 17(6): 1192-202.
[PMID: 26814259]
[PMID: 26814259]
[23]
Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28(11): 1625-31.
[http://dx.doi.org/10.1002/ptr.5174] [PMID: 24853120]
[http://dx.doi.org/10.1002/ptr.5174] [PMID: 24853120]
[24]
Farid R, Rezaieyazdi Z, Mirfeizi Z, et al. Oral intake of purple passion fruit peel extract reduces pain and stiffness and improves physical function in adult patients with knee osteoarthritis. Nutr Res 2010; 30(9): 601-6.
[http://dx.doi.org/10.1016/j.nutres.2010.08.010] [PMID: 20934601]
[http://dx.doi.org/10.1016/j.nutres.2010.08.010] [PMID: 20934601]
[25]
Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res 2009; 58(12): 899-908.
[http://dx.doi.org/10.1007/s00011-009-0063-1] [PMID: 19579007]
[http://dx.doi.org/10.1007/s00011-009-0063-1] [PMID: 19579007]
[26]
Shen CL, Smith BJ, Lo DF, et al. Dietary polyphenols and mechanisms of osteoarthritis. J Nutr Biochem 2012; 23(11): 1367-77.
[http://dx.doi.org/10.1016/j.jnutbio.2012.04.001] [PMID: 22832078]
[http://dx.doi.org/10.1016/j.jnutbio.2012.04.001] [PMID: 22832078]
[27]
Haroyan A, Mukuchyan V, Mkrtchyan N, et al. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complement Altern Med 2018; 18(1): 7.
[http://dx.doi.org/10.1186/s12906-017-2062-z] [PMID: 29316908]
[http://dx.doi.org/10.1186/s12906-017-2062-z] [PMID: 29316908]
[28]
Sutipornpalangkul W, Morales NP, Harnroongroj T. Free radicals in primary knee osteoarthritis. J Med Assoc Thai 2009; 92(Suppl. 6): S268-74.
[PMID: 20120698]
[PMID: 20120698]
[29]
Abramson SB. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 2008; 10(Suppl. 2): S2.
[http://dx.doi.org/10.1186/ar2463] [PMID: 19007427]
[http://dx.doi.org/10.1186/ar2463] [PMID: 19007427]
[30]
Ak T, Gülçin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008; 174(1): 27-37.
[http://dx.doi.org/10.1016/j.cbi.2008.05.003] [PMID: 18547552]
[http://dx.doi.org/10.1016/j.cbi.2008.05.003] [PMID: 18547552]
[31]
Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67(12): 1716-23.
[http://dx.doi.org/10.1136/ard.2008.092015] [PMID: 18541604]
[http://dx.doi.org/10.1136/ard.2008.092015] [PMID: 18541604]
[32]
Zou K, Wong J, Abdullah N, et al. Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2016; 75(11): 1964-70.
[http://dx.doi.org/10.1136/annrheumdis-2015-208387] [PMID: 26882927]
[http://dx.doi.org/10.1136/annrheumdis-2015-208387] [PMID: 26882927]
[33]
Mazzuca SA, Brandt KD, Katz BP, Ding Y, Lane KA, Buckwalter KA. Risk factors for progression of tibiofemoral osteoarthritis: an analysis based on fluoroscopically standardised knee radiography. Ann Rheum Dis 2006; 65(4): 515-9.
[http://dx.doi.org/10.1136/ard.2005.039115] [PMID: 16166105]
[http://dx.doi.org/10.1136/ard.2005.039115] [PMID: 16166105]
[34]
Onakpoya IJ, Spencer EA, Perera R, Heneghan CJ. Effectiveness of curcuminoids in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized clinical trials. Int J Rheum Dis 2017; 20(4): 420-33.
[http://dx.doi.org/10.1111/1756-185X.13069] [PMID: 28470851]
[http://dx.doi.org/10.1111/1756-185X.13069] [PMID: 28470851]
[35]
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15(12): 1833-40.
[PMID: 3068365]
[PMID: 3068365]
[36]
McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum 2001; 45(5): 453-61.
[http://dx.doi.org/10.1002/1529-0131(200110)45:5<453:AID-ART365>3.0.CO;2-W] [PMID: 11642645]
[http://dx.doi.org/10.1002/1529-0131(200110)45:5<453:AID-ART365>3.0.CO;2-W] [PMID: 11642645]
Article Metrics
114
16
1
